Compare RMD & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMD | GEHC |
|---|---|---|
| Founded | 1989 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4B | 38.9B |
| IPO Year | 1995 | N/A |
| Metric | RMD | GEHC |
|---|---|---|
| Price | $253.15 | $79.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $291.10 | $88.27 |
| AVG Volume (30 Days) | 880.0K | ★ 2.9M |
| Earning Date | 01-29-2026 | 02-04-2026 |
| Dividend Yield | ★ 0.93% | 0.17% |
| EPS Growth | 29.59 | ★ 32.35 |
| EPS | ★ 9.77 | 4.83 |
| Revenue | $5,257,400,000.00 | ★ $20,246,000,000.00 |
| Revenue This Year | $9.85 | $6.33 |
| Revenue Next Year | $7.34 | $4.32 |
| P/E Ratio | $26.36 | ★ $16.92 |
| Revenue Growth | ★ 9.36 | 3.51 |
| 52 Week Low | $199.92 | $57.65 |
| 52 Week High | $293.81 | $94.80 |
| Indicator | RMD | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 37.59 |
| Support Level | $240.00 | $84.59 |
| Resistance Level | $261.36 | $87.60 |
| Average True Range (ATR) | 5.40 | 2.24 |
| MACD | 1.27 | -0.82 |
| Stochastic Oscillator | 60.56 | 5.06 |
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).